*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
A Systematic Review on Technical Aspects in the Development of Dry Powder Inhalers (DPI)

Author: PRIYANKA SATISH GONDHALE, DR. BINOY VARGHESE CHERIYAN
Abstract: Bronchial asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF) are diseases characterized by chronic inflammation and increased mucus secretion leading to airflow limitation, parenchymal destruction and the development of chronic dyspnea. Many patients with COPD are further affected by acute exacerbations which results in lung malfunction, decreases quality of life and mortality. Dry powder inhalers are dry free flowing powdered formulations of the drug, prepared by either spray-drying or micronization of a blend consisting of the drug and suitable inert carrier. DPI formulations are delivered as an aerosol by using DPI devices. DPI is a choice for drug delivery as they are easy to operate and has greater patient compliance. Most of the DPIs are bronchodilators, (salmeterol), corticosteroids (Budesonide, Fluticasone) and Anticholinergics (Tiotropium).Combination of bronchodilators with corticosteroids and anticholinergic drug can be used for effective management of pulmonary diseases. The drug particles which are delivered to the lungs are below 5 µm, this is achieved by drug molecules blending with carrier particles preferably lactose to help provide bulk and facilitate dispersion mechanism. DPI formulations are widely accepted. A major concern among physicians in their daily clinical practices is that inter and intra patient variability of the drug dosage delivered to the deep lungs from the inhalation devices. This variability is dependent on drug formulation, its design and patient inhalation profile. This article is a compilation of various issues observed in the development of DPI’s.
Keyword: Dry powder inhalers, Fine particle dose, uniformity of delivered dose, dose sampling tube apparatus (DUSA), Aerodynamic particle size distribution (APSD), Next generation impactor (NG
DOI: https://doi.org/10.31838/ijpr/2021.13.01.688
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free